Chronic lymphocytic leukaemia (CLL) is characterised by the clonal expansion of CD5 + B lymphocytes, which accumulate in the blood, bone marrow, and secondary lymphoid organs. A dynamic interplay ...
Flow cytometry (FC) is essential for detecting measurable residual disease (MRD) in chronic lymphocytic leukemia (CLL), but its use is limited by the expertise and time required for manual analysis.
Treatment of chronic lymphocytic leukemia (CLL) currently consists of two main approaches — continuous therapy with Bruton’s tyrosine kinase inhibitors and fixed-duration regimens combining venetoclax ...
Jaypirca demonstrated superior overall response rates and progression-free survival trends compared to Imbruvica in the BRUIN CLL-314 trial for CLL/SLL patients. The trial is the first head-to-head ...
MLR may be a useful marker for assessing activity and progression in chronic lymphocytic leukemia (CLL). Patients with CLL had significantly lower MLR values compared to healthy individuals, with ...
Chronic lymphocytic leukemia (CLL) treatment options depend on your diagnosis. In earlier stages, “watchful waiting” may be recommended. More advanced CLL may require a combination of therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results